article_id,title,link,keywords,creator,description,content,pubDate,pubDateTZ,image_url,video_url,source_id,source_name,source_priority,source_url,source_icon,language,country,category,sentiment,sentiment_stats,ai_tag,ai_region,ai_org,duplicate
e9abfd71084b147f3ba54568f7059afc,"Myeloproliferative Neoplasms Treatment Market Future Business Opportunities 2025-2032 | Novartis AG, PharmaEssentia Corporation, Bristol Myers Squibb, Pfizer, Inc.",https://www.openpr.com/news/3968455/myeloproliferative-neoplasms-treatment-market-future,['health & medicine'],['Coherent Market Insights'],"Myeloproliferative Neoplasms Treatment Market is estimated to be valued at USD 9.71 Bn in 2025 and is expected to reach USD 12.69 Bn in 2032, exhibiting a compound annual growth rate (CAGR) of 3.9% from 2025 to 2032.A new study",ONLY AVAILABLE IN PAID PLANS,2025-04-14 04:50:04,UTC,https://cdn.open-pr.com/L/4/L414565581_g.jpg,,openpr,Openpr.com,36018,https://www.openpr.com,https://i.bytvi.com/domain_icons/openpr.png,english,['germany'],['health'],ONLY AVAILABLE IN PROFESSIONAL AND CORPORATE PLANS,ONLY AVAILABLE IN PROFESSIONAL AND CORPORATE PLANS,ONLY AVAILABLE IN PROFESSIONAL AND CORPORATE PLANS,ONLY AVAILABLE IN CORPORATE PLANS,ONLY AVAILABLE IN CORPORATE PLANS,False
1ceb8fce495209ab2d7aa44366e6698d,"Recurrent Glioblastoma Multiforme Treatment Market Generated Opportunities, Future Scope 2025-2032 | GlaxoSmithKline plc., AstraZeneca, Pfizer, Inc.",https://www.openpr.com/news/3968372/recurrent-glioblastoma-multiforme-treatment-market-generated,['health & medicine'],['Coherent Market Insights'],"A new study titled Recurrent Glioblastoma Multiforme Treatment Market 2024, published by the Coherent Market Insights, offers information on regional and global markets that is expected to increase in value between 2024 and 2031. The extensive research offers important visions",ONLY AVAILABLE IN PAID PLANS,2025-04-14 03:33:10,UTC,https://cdn.open-pr.com/L/4/L414510908_g.jpg,,openpr,Openpr.com,36018,https://www.openpr.com,https://i.bytvi.com/domain_icons/openpr.png,english,['germany'],['health'],ONLY AVAILABLE IN PROFESSIONAL AND CORPORATE PLANS,ONLY AVAILABLE IN PROFESSIONAL AND CORPORATE PLANS,ONLY AVAILABLE IN PROFESSIONAL AND CORPORATE PLANS,ONLY AVAILABLE IN CORPORATE PLANS,ONLY AVAILABLE IN CORPORATE PLANS,False
5c874a3e9eda50a5cb56b9f5669ce3ce,Pfizer Inc. (NYSE:PFE) Receives Average Recommendation of “Moderate Buy” from Analysts,https://www.americanbankingnews.com/2025/04/13/pfizer-inc-nysepfe-receives-average-recommendation-of-moderate-buy-from-analysts.html,"['market news', 'consensus rating articles']",['ABMN Staff'],"Shares of Pfizer Inc. (NYSE:PFE – Get Free Report) have been assigned a consensus recommendation of “Moderate Buy” from the seventeen analysts that are presently covering the company, Marketbeat.com reports. One equities research analyst has rated the stock with a sell recommendation, eight have assigned a hold recommendation, five have given a buy recommendation and [...]",ONLY AVAILABLE IN PAID PLANS,2025-04-13 07:37:04,UTC,https://www.marketbeat.com/logos/pfizer-inc-logo-1200x675.png?v=20221020143129,,americanbankingnews,Americanbankingnews,125270,https://www.americanbankingnews.com,https://i.bytvi.com/domain_icons/americanbankingnews.jpg,english,['united states of america'],['business'],ONLY AVAILABLE IN PROFESSIONAL AND CORPORATE PLANS,ONLY AVAILABLE IN PROFESSIONAL AND CORPORATE PLANS,ONLY AVAILABLE IN PROFESSIONAL AND CORPORATE PLANS,ONLY AVAILABLE IN CORPORATE PLANS,ONLY AVAILABLE IN CORPORATE PLANS,False
